Eiko Lifesciences Ltd Directors Report

To,

The Members,

Eiko LifeSciences Limited

604, Centrum, Opp. TMC Office,

Near Satkar Grande Hotel, Wagle Estate,

Thane, Maharashtra – 400604.

Your directors have pleasure in presenting the 49th Annual Report together with the Audited Standalone and Consolidated statement of accounts for the year ended 31st March 2026.

1. FINANCIAL SUMMARY

(Rs in Lakhs)

Particulars	Consolidated 2025-26	Consolidated 2024-25	Standalone 2025-26	Standalone 2024-25
Revenue from operations	5,257.14	3,766.40	4,212.68	3,249.18
Other Income	110.80	71.61	212.93	102.40
Total Income	5,367.94	3,838.01	4,425.61	3,351.58
Total Expenses	4,661.47	3,579.97	3,954.31	3,153.88
Profit/(Loss) Before Tax	711.77	306.49	471.30	231.82
Profit/(Loss) After Tax	532.47	231.86	358.11	174.08
Earnings per Share: Basic	3.26	1.62	2.60	1.34
Diluted	3.19	1.62	2.54	1.34

2. OPERATIONS:

The Company continues to strengthen its presence as a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and APIs. During the year under review, the Company remained focused on consolidating the strategic initiatives undertaken in the previous year while exploring opportunities for sustainable growth and diversification across allied business segments.

Key Strategic Developments

- Strategic forward-integration move into pharmaceutical formulations through acquisition of 51% stake in SSM Formulations Private Limited

During the year, the Company executed a definitive agreement to acquire a 51% equity stake in SSM Formulations Private Limited a pharmaceutical formulations company having a WHO-GMP accredited manufacturing facility at Hinganghat, Wardha, Maharashtra. This acquisition marks a transformative milestone, evolving the Company from a specialty chemicals and API supplier into a fully integrated pharmaceutical player with a global footprint in Finished Dosage Forms (FDF). The Company will now be able to manufacture finished formulations utilizing its own API supply chain, allowing us to capture full value-chain margins.

- Financial Highlights

The Company delivered an exceptional financial performance for the fiscal year 2025-26, demonstrating robust growth in both turnover and profitability across standalone and consolidated bases.

- Consolidated Performance:

o Revenue from Operations: Grew significantly by 39.58%, reaching Rs5,257.14 Lakhs in FY 2025-26, compared to Rs3,766.40 Lakhs in the previous year.

o Profit After Tax (PAT): Surged by 129.65%, standing at Rs532.47 Lakhs in FY 2025-26, up from Rs231.86 Lakhs in FY 2024-25.

- Standalone Performance:

o Revenue from Operations: Increased by 29.65% to Rs4,212.68 Lakhs in FY 2025-26, up from Rs3,249.18 Lakhs in the preceding year.

o Profit After Tax (PAT): Grew by 105.72%, closing at Rs358.11 Lakhs in FY 2025-26, compared to Rs174.08 Lakhs in FY 2024-25.

3. DIVIDEND:

Your Board does not recommend any Final Dividend for the Financial Year 2025-26.

4. CHANGES IN SHARE CAPITAL:

At the start of the financial year, the issued, subscribed, and paid-up Equity Share Capital of the Company stood at Rs13,72,08,540 (Rupees Thirteen Crore Seventy-Two Lakhs Eight Thousand Five Hundred and Forty only).

On 24th February 2026, the Company allotted 6,25,000 (Six Lakh Twenty-Five Thousand) Equity Shares of face value of Rs. 10/- (Rupees Ten Only) each fully paid-up at a price of Rs. 55/- per equity share (including premium of Rs. 45/- per Equity Share), to the Members belonging to the Promoters and Promoters Group.

Further, the Company has allotted 29,50,000 (Twenty-Nine Lakhs Fifty Thousand) Warrants, each Warrant convertible into 1 (one) Equity Share of Face Value of Rs. 10/- (Rupees Ten Only) each at a price of Rs. 55/- per equity share (including premium of Rs. 45 per Equity Share) to the Members belonging to the Promoters and Promoters Group along with Public Category.

Further, Rs. 4,05,62,500/- (being 25% of total amount of Rs. 16,22,50,000/-) have been received on Allotment of Warrants by the Company and rest 75% will be received at the time of Conversion of Warrants into Equity Shares.

At the end of the financial year, the issued, subscribed, and paid-up Equity Share Capital of the Company stood at Rs. 14,34,58,540/- (Rupees Fourteen Crore Thirty-Four Lakhs Fifty-Eight Thousand Five Hundred and Forty only).

As on report date, the Company has allotted 3,05,000 Equity Shares to allottees, pursuant to exercise of conversion Rights attached with Warrants issued on 24th February 2026.

5. TRANSFER OF UNPAID/ UNCLAIMED DIVIDEND:

The Company does not have any unpaid / unclaimed amount which is required to be transferred, under the provisions of the Companies Act, 2013 into the Investor Education and Protection Fund (‘IEPF) of the Government of India.

There is no other statutory amount like outstanding unpaid Refund Amount on Share Applications, unpaid interests or principal of Deposits and Debentures, etc. lying with the company which are required to be transferred to the IEPF.

6. TRANSFER TO RESERVES:

The Board of Directors have not appropriated and transferred any amount to any reserve and the Board has decided to retain the entire amount in the profit and loss account.

7. DEPOSITS:

During the year under review, your Company did not accept any deposits in terms of Section 73 of the Companies Act, 2013 ("the Act") read with the Companies (Acceptance of Deposit) Rules, 2014. No amounts were outstanding which were classified as Deposit under the applicable provisions of the Companies Act, 2013 as on the Balance Sheet date.

8. LOANS FROM DIRECTORS

During the financial year under review, the Company has not borrowed any amount(s) from Directors.

9. COMPLIANCE WITH THE LISTING AGREEMENT:

Companys shares are listed on BSE Ltd. w.e.f. 13th December 2016 and Company has complied with the mandatory provisions of Corporate Governance as stipulated in the Listing Agreement with the Stock Exchange.

10. REPORT ON PERFORMANCE OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE COMPANIES:

During the year under review, the Company has two Subsidiaries and two Associates, which are as follows:

Sr. No.	Name of Body Corporate	Identification No.	Relation
1	Eiko Scientific Solutions LLP	LLPIN: ACH-4311	Wholly Owned Subsidiary
2	EikoVivify Logistics Private Limited	CIN: U77308MH2024PTC434438	Subsidiary
3	Reflux Pharmaceuticals Private Limited	CIN: U74999MH2020PTC337046	Associate Company
4	SSM Formulations Private Limited	CIN: U24233MH2012PTC237383	Associate Company

Apart from above, there are no Holding /Subsidiary/Joint Venture/ Associate Company.

The Consolidated Financial Statements of the Company for the year ended March 31, 2026 are prepared in compliance with the applicable provisions of the Companies Act, 2013, and as stipulated under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). The Audited Consolidated Financial Statements together with the Auditors Report thereon forms part of the Annual Report.

Pursuant to Section 129(3) of the Companies Act, 2013, Statement containing salient features of the Financial Statements of the Subsidiary Companies in the prescribed Form AOC-1 is appended as Annexure – "A" to this report.

Pursuant to the provisions of Section 136 of the Companies Act, 2013, the Financial Statements of the Subsidiary Companies are kept for inspection by the Members at the Registered Office of the Company.

The Company will provide a copy of the Financial Statements of its Subsidiary Companies to the Members upon their request.

11. SIGNIFICANT OR MATERIAL ORDER PASSED BY REGULATORS/ COURTS:

During the year under review, there were no significant or material orders passed by the regulators or court or tribunals impacting the going concern status and Company Operations in future.

12. REPORT ON CORPORATE GOVERNANCE:

As per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Corporate Governance Report with the Auditors Certificate thereon forms part of this Annual Report.

13. MANAGEMENT DISCUSSION AND ANALYSIS:

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Management Discussion and Analysis forms part of this Annual Report.

14. RELATED PARTY TRANSACTION:

The Company has historically adopted the practice of undertaking related party transactions only in the ordinary and normal course of business and at arms length as part of its philosophy of adhering to highest ethical standards, transparency, and accountability. All related party transactions that were entered with your Company, during the financial year were on arms length basis and were in the ordinary course of the business. In terms of the Act, material related party transactions entered into by your Company with its subsidiary and other related parties are covered in Form AOC - 2 attached as Annexure – "B" to this report.

As per the policy on Related Party Transactions as approved by the Board of Directors, Company had entered into related party transactions based upon the omnibus approval granted by the Audit Committee. On half-yearly basis, the Audit Committee reviews such transactions, for which such omnibus approval was given. Further, during the year under review, the policy on Related Party Transactions was revised in view of amendments in applicable rules.

The policy on Related Party Transactions as amended and approved by the Board of Directors, is accessible on your Companys website at- www.eikolifesciences.com

15. DISCLOSURE OF INFORMATION AS REQUIRED UNDER SECTION 134 (3)(M) OF THE COMPANIES ACT, 2013 (ACT) READ WITH THE COMPANIES (ACCOUNTS) RULES, 2014:

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of The Companies (Accounts) Rules,2014, is annexed hereto and marked as Annexure – "C" to this report.

16. ANNUAL RETURN

Pursuant to Section 134(3)(a) of the Act read with Section 92(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014, Annual Return is published on the Companys website at www.eikolifesciences.com. The final Annual Return shall be uploaded in the same web link after the said Return is filed with the Registrar of Companies, within the statutory timelines.

17. AUDITORS & REPORTS:

a. Statutory Auditors:

Pursuant to the provisions of Section 139 of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014, M/s. P S V Jain & Associates Chartered Accountants (FRN: 131505W) were appointed as Statutory Auditors of the Company for a period of five consecutive years, commencing from the conclusion of 47th Annual General Meeting held in FY 2024-25, till the conclusion of 52nd Annual General Meeting of the company.

The Auditors have confirmed their availability within the meaning of provisions of Section 139 of the companies Act, 2013.

The Independent Auditors Report for the Financial Year ended March 31, 2026, on the Standalone and Consolidated Financial Statements of the Company forms part of this Annual Report.

There are no qualifications or reservation or adverse remarks or disclaimers in the said report. The Auditors Report are self-explanatory and do not call for any further comments.

b. Secretarial Audit:

Pursuant to the provisions of section 204 of the Companies Act, 2013, M/s Shravan A. Gupta & Associates, Practicing Company Secretaries, were appointed as the Secretarial Auditor to undertake Secretarial Audit of the Company for a period of five consecutive years, commencing from Financial Year 2025-26 till Financial year 2029-30.

The Secretarial Audit Report for the F.Y. 2025-26 as required under the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of the SEBI Listing Regulations, is set out in Annexure – "D" to this Report.

The Secretarial Audit Report for FY 2025-26 does not contain any qualification, reservation or adverse remark or disclaimer made by the secretarial auditor.

In addition to the above and pursuant to SEBI circular dated 8th February 2019 and as per Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a report on Secretarial Compliance by M/s Shravan A. Gupta & Associates for FY 2025-26 is submitted to stock exchange. There are no observations, reservations or qualifications in the said report.

Further, in terms of the Listing Regulations and as per Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 of the Secretarial Audit Report of EikoVivify Logistics Private Limited, Unlisted Material Subsidiary of the Company, issued by M/s Shravan A. Gupta & Associates, Practicing Company Secretaries, is also enclosed as Annexure – "D-1" to this Report.

c. Cost Audit and Cost Records:

Pursuant to the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company is not required to maintain Cost Records under said Rules.

d. Internal Auditors of the Company:

The Company has adopted an internal control system, commensurate with its size. The Company had appointed M/s N P Rajput & Co. Chartered accountant as the Internal Auditor of the Company for Financial Year 2025-26.

There are no adverse remarks by Internal Auditor in their report for the financial Year ended 31st March 2026.

e. Reporting by Statutory Auditors:

There were no incidents of reporting of frauds by Statutory Auditors of the Company under Section 143 (12) of the Act read with Companies (Accounts) Rules, 2014.

f. Code for prevention of Insider Trading:

As per Securities and Exchange Board of India (Prohibition of Insider Trading Regulations), 2015, your Company has adopted an amended Code of Conduct to regulate, monitor and report trading by Designated Persons and their Immediate Relatives under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. This Code of Conduct also includes code of practices and procedures for fair disclosure of unpublished price sensitive information and has been made available on the Companys website at www.eikolifesciences.com.

18. UPDATION OF EMAIL IDS FOR RECEIVING NOTICES / DOCUMENTS IN ELECTRONIC MODE:

Shareholders who have not registered their email addresses with the depositories are requested to register their email addresses with the Registrar and Share Transfer Agent (RTA) of the Company to enable the RTA to deliver notices /documents through e-mode. Shareholders holding their shares in DEMAT mode have to register their email addresses with their depository, through their depository participant.

19. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The Company maintains adequate internal control systems, which provide, amongst other things, adequate support to all its operations and effectively handle the demands of the Companys financial management systems. The Company has in place effective systems safeguarding the assets and interest of the Company and ensuring compliance with laws, rules and regulations. The Companys internal control systems are supplemented by an extensive program of internal audit conducted by an external auditor to ensure adequate system of internal control.

20. DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to the provisions of Section 134 (5) of Companies Act, 2013, as amended, with respect to the Directors Responsibility Statement, it is hereby confirmed that:

a. In the preparation of the accounts for the financial year ended 31st March 2026, the applicable Accounting Standards have been followed along with proper explanation relating to material departures.

b. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as of 31st March 2026 and of the profit and loss of the Company for the year ended 31st March 2026.

c. The Directors have taken proper and enough care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

d. The Directors have prepared the annual accounts for the financial year ended 31st March 2026 on a going concern basis.

e. The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively.

f. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

21. SECRETARIAL STANDARDS ISSUED BY ICSI:

Your Company is in compliance with the Secretarial Standards on Meetings of the Board of Directors (SS - 1) and General Meetings (SS - 2) issued by The Institute of Company Secretaries of India and approved by the Central Government.

22. COMMITTEES OF BOARD OF DIRECTORS OF THE COMPANY:

Following are the Committees of Board of Directors of the Company. The Composition of the following Committees are hosted on the website of the Company and details of the following committees has been mentioned in the Corporate Governance Report.

a. Audit Committee:

The Audit Committee of Directors was constituted as per Regulation 18 of SEBI (LODR) Regulation 2015. The composition of the Audit Committee and its meetings during the Financial Year 2025-26 is in conformity with the provisions said above regulations.

The details of number of meetings held by the Audit committee in the year under review and other related details are given in the Corporate Governance Report.

During the year under review, Board has accepted all the recommendation made by the committee

b. Nomination and Remuneration Committee:

The Nomination and Remuneration Committee was constituted pursuant to the provision of section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (LODR) Regulation, 2015

The terms of reference of the Committee, inter alia, includes formulation of criteria for determining qualifications, positive attributes and independence of a director, recommendation of persons to be appointed to the Board and senior management, devising a Policy on Board diversity, specifying the manner for effective evaluation of performance of Board, its Committees, Chairperson and individual directors, recommendation of remuneration policy for directors, key managerial personnel and other employees, formulation of criteria for evaluation of performance of independent directors and the Board, etc. The Committee also reviews the remuneration of the senior management team. More details on the terms of reference of the Committee are placed on Company website at www.eikolifesciences.com.

c. Stakeholders Relationship Committee:

The Stakeholders Relationship Committee was constituted pursuant to the provisions of Section 178 of the Companies Act, 2013 and Regulation 20 of SEBI (LODR) Regulation, 2015.

d. Corporate Social Responsibility:

The provisions relating to Corporate Social Responsibility (CSR) under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 are applicable to every company meeting the prescribed threshold criteria relating to net worth, turnover or net profit.

During the financial year under review, the Company did not meet the prescribed criteria for the applicability of the CSR provisions. Accordingly, the provisions of Section 135 of the Companies Act, 2013 and the Rules made thereunder were not applicable to the Company, and no CSR Committee was required to be constituted.

e. Rights Issue Committee

The Rights Issue Committee constituted by the Board pursuant to applicable SEBI Regulations for the purpose of the Rights Issue was dissolved with effect from 29th January, 2026, upon completion of the Rights Issue and related activities.

23. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:

The Company was not in the Top 1,000 companies as per Market Capitalisation as on 31st March 2026, at the Stock Exchange, where it is listed namely - BSE Limited. Accordingly, the Company is not required to submit a Business Responsibility and Sustainability Report (which replaces the earlier requirement of a Business Responsibility report) in view of Regulation 34 read with Regulation 3(2) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

24. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONS:

RETIREMENT BY ROTATION:

The Company in total has 6 directors as on 31st March 2026–

- Five Non-executive Directors (including 3 Independent Directors)

- One Executive Director (Whole time Director)

As per the provisions of Act, not less than two-thirds of the total number of directors (excluding independent directors & WTD) are liable to retire by rotation, and one-third of such rotational directors retire at every Annual General Meeting and, being eligible, offer themselves for re-appointment. Amongst the said 2 directors, Mr. Bhavesh Dhirajlal Tanna have been longest in office since his last appointment and is liable to retire by rotation and being eligible, has offered himself for re-appointment.

Your Directors recommend his re-appointment in accordance with the provisions of the Act and the said Director is not disqualified from being re-appointed as a Director of a Company as per the disclosure received from him pursuant to Section 164 (2) of the Act.

Brief details of Mr. Bhavesh Dhirajlal Tanna, Director, who is seeking re-appointment, are given in the notice of AGM.

CHANGES IN KMP:

Mr. Umesh Ravindranath More (DIN: 09044162), Whole Time Director of the Company resigned w.e.f. 29th July, 2025 and Mr. Sumukh Prabhakar Vartak (DIN: 10977198) was appointed as a Whole Time Director.

CHANGE IN DESIGNATION OF DIRECTORS:

During the year under review, Designation of Mr. Sumukh Vartak, was changed from Additional Whole Time Director to Whole Time Director, upon regularization at the Annual General Meeting.

As on report date, Ms. Hasti Doshi, Independent Director of the Company has resigned w.e.f. closing hours of 24th August, 2026 and Mr. Suraj Mahadev Gaikwad has been appointed as an Additional Director (Independent and Non-Executive) w.e.f. 24th August, 2026.

25. MATTERS RELATED TO DIRECTORS:

a. Independent Directors Declaration:

The Independent Directors have submitted a declaration of Independence, stating that they meet the criteria of independence as stipulated under the Act, as amended, and SEBI Listing Regulations. The Independent Directors have also confirmed compliance with the provisions of Rule 6 of Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended, relating to inclusion of their name in the databank of Independent Directors.

Pursuant to the Companies (Appointment and Qualification of Directors) Rules, 2014, the Independent Directors are registered with MCA Independent Directors Databank.

In the opinion of the Board, the Independent Directors of the Company possess the requisite qualifications, experience (including proficiency), expertise and integrity. The terms and conditions of appointment of Independent Directors are also available on the Companys website at www.eikolifesciences.com.

b. Performance Evaluation:

The Company has a policy for performance evaluation of the Board, Committees and other Individual Directors (including Independent Directors) which includes criteria for performance evaluation of Non-executive Directors and Executive Directors. In accordance with the manner of evaluation specified by the Nomination and Remuneration Committee, the Board carried out annual performance evaluation of the Board, its Committees and Individual Directors. The Independent Directors carried out annual performance evaluation of the Chairman, the Non-Independent Directors and the Board as a whole. The Chairperson of the respective Committees shared the report on evaluation with the respective Committee Members. The performance of each Committee was evaluated by the Board, based on the report of evaluation received from respective Committees.

c. Remuneration Policy:

The Board of Directors has upon recommendation of the Nomination & Remuneration Committee framed policy for selection and appointment of Directors and their remuneration which is stated in the Corporate Governance Report.

d. Number of Board Meetings:

The Board met 6 (Six) times during the financial year ended 31st March 2026 in accordance with the provisions of the Act, the details of which are given in the Corporate Governance Report.

e. Independent Directors Meeting

A separate meeting of the Independent Directors without the presence of the Chairman, or other Non-Independent Director(s) or any other Management Personnel was held on Thursday, 29th January, 2026.

The Independent Directors reviewed the performance of Non-Independent Directors, Committees of the Board and the Board as a whole along with the performance of the Chairman of the Company and assessed the quality, quantity and timeliness of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

f. Familiarization Program for Independent Director

All Independent Directors are familiar with the operations and functioning of the Company at the time of their appointment and on an ongoing basis. The details of the training and familiarization program are provided in the Corporate Governance Report and is also available website of the Company at www.eikolifesciences.com.

26. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS BY THE COMPANY:

Pursuant to the provisions of Section 186 of the Companies Act, 2013 read with The Companies (Meetings of Board and its Powers) Rules, 2014, Particulars of Loans, Guarantees and Investments by the Company has been furnished in the Notes to Audited financial statement which forms part of this Annual Report.

27. PARTICULARS OF THE EMPLOYEES:

Pursuant to Section 197(12) of the Companies Act, 2013 and Rule 5(1) of the Companies (Appointment and Remunerations of Managerial Personnel) Rules, 2014, the relevant details for financial year 2025-26 are annexed as Annexure "E" to this Report.

It is hereby affirmed that the remuneration paid is as per the Remuneration Policy of your Company. Further, as per Sec 197 (12) of Companies Act, 2013 read with Rule 5 (2) and Rule 5 (3) of the aforesaid Rules, the Statement containing names and details of the top ten employees in terms of remuneration drawn during the financial year 2025-26 forms part of this report.

Having regard to the provisions of the second proviso to Section 136(1) of the Act and as advised, the Annual Report excluding the aforesaid information is being sent to the Members of the Company. This Statement is open for inspection at the Registered Office of the Company during working hours, and any member interested in obtaining such particulars may write to the Company Secretary of the Company.

28. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

Provisions of the sexual harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013 does not apply to your company as number of female employees in the company are below 10 and no Committee were formed.

There were no cases/complaints filed during the year, under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("Act").

During the Financial Year 2025-26
Number of complaints received	0
Number of complaints disposed of	Not Applicable
Number of cases pending for more than 90 days	Not Applicable

29. COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961

The Company has complied with the applicable provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the benefits as prescribed under the Act. The Company remains committed to supporting working mothers and promoting a gender-inclusive workplace.

30. ESTABLISHMENT OF VIGIL MECHANISM:

Pursuant to the provisions of Section 177 (9) of the Act read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, and Regulation 22 of SEBI (LODR) Regulations 2015, the Company already has in place "Vigil Mechanism Policy" (Whistle Blower Policy) for Directors and employees of the Company to provide a mechanism which ensures adequate safeguards to employees and Directors from any financial statements and reports, etc.

The employees of the Company have the right/option to report their concern/grievance to the Chairman of the Audit Committee. The Company is committed to adhere to the highest standards of ethical, moral and legal conduct of business operations. The details of the same are mentioned in the Corporate Governance Report.

The policy has been hosted on the Companys website at www.eikolifesciences.com.

31. LEGAL AND REGULATORY:

Compliance with laws and regulations is an essential part of your Companys business operations. We are subject to laws and regulations in diverse areas as product safety, product claims, trademarks, copyright, patents, competition, employee health and safety, the environment, corporate governance, listing and disclosure, employment, and taxes.

Frequent changes in legal and regulatory regime and introduction of newer regulations with multiple authorities regulating same areas lead to complexity in compliance. We closely monitor and review our practices to ensure that we remain compliant with relevant laws and legal obligations.

32. SYSTEM AND INFORMATION:

Your Companys operations are increasingly dependent on IT systems and the management of information. The Company continues to strengthen its information technology infrastructure to support efficient business operations and secure management of information. Robust security measures, including firewalls, access controls, and continuous system monitoring, are in place to safeguard the Companys digital assets and information systems.

The Company remains committed to maintaining a secure and reliable IT environment through regular system enhancements and employee awareness initiatives, thereby ensuring business continuity and data protection.

33. GENERAL DISCLOSURES:

Your directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

a. The Company has not issued any shares with differential rights and hence no information as per provisions of Section 43(a)(ii) of the Act read with Rule 4(4) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

b. The Company has not issued any sweat equity shares during the year under review and hence no information as per provisions of Section 54(1)(d) of the Act read with Rule 8(13) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

c. The Company has not issued any equity shares under Employees Stock Option Scheme during the year under review and hence no information as per provisions of Section 62(1)(b) of the Act read with Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

d. During the year under review, there were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014.

34. CAUTIONARY STATEMENT:

Statements in the Boards Report and the Management Discussion & Analysis describing the Companys objectives, expectations or forecasts may be forward-looking within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Important factors that could influence the Companys operations include global and domestic demand and supply, input costs, availability, changes in government regulations, tax laws, economic developments within the country and other factors such as litigation and industrial relations.

35. OTHER STATUTORY DISCLOSURES:

- There has been no change in business of the Company.

- There was no instance of onetime settlement with any Bank or Financial Institution.

- During the year under review, there were no proceeding made nor were any pending under the Insolvency and Bankruptcy Code, 2016.

36. SHARE TRANSFER SYSTEM:

Share transfers and related operations for the Company are processed by the Companys RTA viz., Bigshare Services Private Limited, share transfer is normally affected within the maximum period of 15 days from the date of receipt, if all the required documentation is submitted.

Securities and Exchange Board of India (SEBI) vide its notification dated June 8, 2018, has notified Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Fourth Amendment) Regulations, 2018 (Listing Regulations) and SEBI (Registrars to an Issue and Share Transfer Agents) (Amendment) Regulations 2018 (RTA Regulations) and amendment to Regulation 40 of the Listing Regulations and Clause 5(c) of Schedule III of the RTA Regulations. These amendments have mandated that the transfer of securities would be carried out only in dematerialized form.

Accordingly, attention of all the shareholders holding shares in physical form is brought to the following:

Request for effecting transfer of securities shall not be processed by the Company or Bigshare Services Private Limited, Registrar and Share Transfer Agents (RTA) of the Company, unless the securities are held in dematerialized form with effect from 01 April 2020. Subject to SEBI circular SEBI/HO/MIRSD/MIRS-PoD/P/CIR/2025/97 dated July 02, 2025, read with circular No. HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026 enabling a special window for re-lodgement of transfer deeds of physical shares, which shall be open till 4th February, 2026. Further, SEBI vide their circular HO/38/13/11(2)/2026-MIRSD-POD/I/3750/2026 dated 30th January, 2026 has extended the special window for a period of one year from 5th February, 2026 to 4th February, 2027.

37. RISK MANAGEMENT:

The Board of Directors of the Company has not designed any Risk Management Policy. However, the Company has in place mechanism to identify, assess, monitor and mitigate various risks to key business objectives. Major risks identified are systematically addressed through mitigating actions on a continuing basis.

38. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:

There have been no material changes and commitments, affecting the financial position of the Company which has occurred between the end of the financial year of the Company to which the financial statements relate and date of this Report.

39. ISIN:

The Companys International Security Identification Number (ISIN) for its equity shares issued in Dematerialized Form is INE666Q01016.

ACKNOWLEDGEMENT:

Your directors would like to express their deep appreciation to employees at all levels for their hard work, dedication, and commitment.

The Board also places on record its appreciation and gratitude for the continued cooperation and support received by your Company during the year from shareholders, investors, bankers, financial institutions, customers, business partners, all regulatory and government authorities, and other stakeholders.

For and on behalf of the Board

For Eiko LifeSciences Limited

Laxmikant Kabra

Chairman

DIN: 00061346

Date: 24th August 2026

Place: Thane